Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial

AIMS: In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome (ACS) undergoing planned percutaneous coronary intervention....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Murphy, Sabina A., Antman, Elliott M., Wiviott, Stephen D., Weerakkody, Govinda, Morocutti, Giorgio, Huber, Kurt, Lopez-Sendon, Jose, McCabe, Carolyn H., Braunwald, Eugene
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2008
Teme:
Clinical Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2567025/
https://ncbi.nlm.nih.gov/pubmed/18682445
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehn362
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items